These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 20217530)
1. Pulmonary drug delivery: medicines for inhalation. Henning A; Hein S; Schneider M; Bur M; Lehr CM Handb Exp Pharmacol; 2010; (197):171-92. PubMed ID: 20217530 [TBL] [Abstract][Full Text] [Related]
2. Clinical perspectives on pulmonary systemic and macromolecular delivery. Scheuch G; Kohlhaeufl MJ; Brand P; Siekmeier R Adv Drug Deliv Rev; 2006 Oct; 58(9-10):996-1008. PubMed ID: 16996638 [TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
4. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Sakagami M Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1030-60. PubMed ID: 17010473 [TBL] [Abstract][Full Text] [Related]
5. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects. Rogueda PG; Traini D Expert Opin Drug Deliv; 2007 Nov; 4(6):595-606. PubMed ID: 17970663 [TBL] [Abstract][Full Text] [Related]
6. Pulmonary formulations: what remains to be done? Weers JG; Bell J; Chan HK; Cipolla D; Dunbar C; Hickey AJ; Smith IJ J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23 Suppl 2():S5-23. PubMed ID: 21133800 [TBL] [Abstract][Full Text] [Related]
7. The influence of pulmonary surfactant on nanoparticulate drug delivery systems. Schleh C; Rothen-Rutishauser B; Kreyling WG Eur J Pharm Biopharm; 2011 Apr; 77(3):350-2. PubMed ID: 21195761 [TBL] [Abstract][Full Text] [Related]
8. The particle has landed--characterizing the fate of inhaled pharmaceuticals. Patton JS; Brain JD; Davies LA; Fiegel J; Gumbleton M; Kim KJ; Sakagami M; Vanbever R; Ehrhardt C J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23 Suppl 2():S71-87. PubMed ID: 21133802 [TBL] [Abstract][Full Text] [Related]
9. The nanoscale in pulmonary delivery. Part 2: formulation platforms. Rogueda PG; Traini D Expert Opin Drug Deliv; 2007 Nov; 4(6):607-20. PubMed ID: 17970664 [TBL] [Abstract][Full Text] [Related]
10. Nanoparticle formulations in pulmonary drug delivery. Bailey MM; Berkland CJ Med Res Rev; 2009 Jan; 29(1):196-212. PubMed ID: 18958847 [TBL] [Abstract][Full Text] [Related]
11. Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Bitonti AJ; Dumont JA Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1106-18. PubMed ID: 16997417 [TBL] [Abstract][Full Text] [Related]
12. Treating systemic diseases via the lung. Sanjar S; Matthews J J Aerosol Med; 2001; 14 Suppl 1():S51-8. PubMed ID: 11424894 [TBL] [Abstract][Full Text] [Related]
13. In vivo animal models for drug delivery across the lung mucosal barrier. Cryan SA; Sivadas N; Garcia-Contreras L Adv Drug Deliv Rev; 2007 Sep; 59(11):1133-51. PubMed ID: 17900750 [TBL] [Abstract][Full Text] [Related]
14. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Laube BL Respir Care; 2005 Sep; 50(9):1161-76. PubMed ID: 16122400 [TBL] [Abstract][Full Text] [Related]
15. Assessment methods of inhaled aerosols: technical aspects and applications. Jaafar-Maalej C; Andrieu V; Elaissari A; Fessi H Expert Opin Drug Deliv; 2009 Sep; 6(9):941-59. PubMed ID: 19637979 [TBL] [Abstract][Full Text] [Related]
16. The impact of pulmonary diseases on the fate of inhaled medicines--a review. Wang YB; Watts AB; Peters JI; Williams RO Int J Pharm; 2014 Jan; 461(1-2):112-28. PubMed ID: 24291124 [TBL] [Abstract][Full Text] [Related]
17. Inhaled insulin-intrapulmonary, intranasal, and other routes of administration: mechanisms of action. Henkin RI Nutrition; 2010 Jan; 26(1):33-9. PubMed ID: 20005465 [TBL] [Abstract][Full Text] [Related]